Search Cancer Clinical Trials

Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
17 results
  • Cellular Therapy

2024P001014          Phase I

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Single Ascending Doses of SBT777101 in Subjects with Rheumatoid Arthritis

  • Cellular Therapy

24-414          Phase II

A Phase 1/2 Dose Evaluation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9–Engineered T Cells (CTX131) in Adult Subjects With Relapsed/Refractory Hematologic Malignancies

  • Ovarian Cancer, Cellular Therapy

24-570          Phase I

A Phase 1a/1b Study of 27T51, an anti-MUC16 CAR T cell drug product administered alone or in combination for participants with recurrent or refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer

  • Multiple Myeloma, Cellular Therapy

18-604          Phase II

A Phase 2, Multicohort, Open-label, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year of Initial Treatment (KarMMa-2).

  • Cellular Therapy, Multiple Myeloma

24-044          Phase II

A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

  • Lymphoma, Cellular Therapy

20-011          Phase II

A Phase 2, Open-Label, Single-Arm, Multicohort, Multicenter Trial To Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL)

  • Cellular Therapy, Multiple Myeloma

24-556          Phase III

A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of anitocabtagene autoleucel (anito-cel) versus Standard of Care Therapy in Participants with Relapsed/Refractory Multiple Myeloma (iMMagine-3)

  • Multiple Myeloma, Cellular Therapy

20-518          Phase I

A Phase I Clinical Trial with TriPRIL CAR T Cells for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

  • Cellular Therapy, Lymphoma

23-474          Phase I

A Phase I Study of Bivalent CD79b and CD19 Directed CAR T Cells in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

  • Cellular Therapy, Lymphoma

24-421          Phase II

A Randomized, Open-label Study Evaluating The Efficacy And Safety Of Cemacabtagene Ansegedleucel In Participants With Minimal Residual Disease After Response To First Line Therapy For Large B-cell Lymphoma (Alpha3)

Showing 1 - 10 of 17 results